Breast cancer is the most common malignancy in women. The role of BRCA1 genes which modulate or promote cancer has been fully understood. The current status in rational drug design using homology modeling is discussed in this study which focuses on template selection, model building, model verification and strategies for drug design based on the model structures. A novel approach to identify the unique binding site for selected drugs like Anastrozole, Extremestane, Epirubicin and letrozole, based on homology and docking is described.
